What is Ethris?
Ethris operates at the intersection of genetic engineering and respiratory medicine, utilizing a proprietary platform to design and deliver stabilized mRNA directly to the lungs. Unlike traditional therapeutic approaches, the company's nebulization technology allows for targeted, non-immunogenic protein expression, which is critical for treating complex respiratory conditions. As a global leader in mRNA innovation, Ethris has spent over a decade refining its formulation technologies, effectively bridging the gap between genetic discovery and clinical application. Its market position is defined by its ability to address unmet medical needs through highly specialized, patient-centric therapeutic proteins.
How much funding has Ethris raised?
Ethris has raised a total of $59.3M across 3 funding rounds:
Series A
$28M
Series B
$26.3M
Other Financing Round
$5M
Series A (2017): $28M with participation from Orbimed and HS Life Sciences
Series B (2022): $26.3M led by Laureus Capital
Other Financing Round (2024): $5M supported by Bill & Melinda Gates Foundation
Key Investors in Ethris
Bill & Melinda Gates Foundation
A global philanthropic organization dedicated to improving healthcare outcomes and reducing extreme poverty through strategic investments in medical innovation.
Laureus Capital
A venture group comprised of serial entrepreneurs focused on supporting digital innovation, sustainability, and high-growth technology asset classes.
Orbimed
A leading healthcare-dedicated investment firm that provides capital to companies across the life sciences spectrum, from early-stage startups to global enterprises.
What's next for Ethris?
With the recent infusion of capital, Ethris is well-positioned to accelerate the development of its core pipeline, focusing on the transition of its mRNA-based candidates into advanced clinical trials. The strategic focus will likely remain on optimizing its nebulization delivery systems to enhance therapeutic efficacy and patient outcomes. Furthermore, the company is expected to leverage this financial stability to expand its collaborative research efforts, potentially exploring new therapeutic indications for its mRNA platform. As the biotech industry shifts toward more precise, localized delivery mechanisms, Ethris remains a critical player to watch for its potential to redefine standard-of-care treatments for chronic respiratory diseases.
See full Ethris company page
